GW01-200 tablets in people with advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, open-label Phase 1 trial of GW01-200 tablets in participants with advanced solid tumors or hematological malignancies. The study aims to characterize safety, tolerability, pharmacokinetics, and preliminary signs of activity. Eligible patients have measurable disease, good performance status, and adequate organ function after prior therapies. Enrollment is at multiple centers in China, led by Groovy Medicine (Hangzhou) with participating hospitals in Beijing, Langfang, and Hangzhou. Key exclusions include hypersensitivity to the product, recent other malignancies, and active CNS tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Documented locally advanced or metastatic solid tumors or advanced hematological malignancies, with disease progression after standard treatment, or intolerant to standard treatment, or no standard treatment is available.
* Have at least one measurable target lesion.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Minimum life expectancy ≥ 3 months.
* Adequate organ and marrow function.

Exclusion Criteria:

* Participants with a known hypersensitivity to the investigational product(s) or any of the excipients of the product(s).
* History of other primary malignancies, except for those who have been curatively treated and have no known active disease within 5 years prior to the first dose with a very low potential for recurrence, or adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or papillary thyroid cancer with no evidence of disease.
* Presence of primary central nervous system (CNS) tumors or symptomatic brain metastases; prior or current leptomeningeal disease or spinal cord compression.
* Radiographic evidence of tumor invasion into major blood vessels (tumor completely approaching, surrounding, or invading the lumen of major blood vessels such as the pulmonary artery or superior vena cava) or evidence of tumor thrombus.
* Received systemic anti-tumor therapy within 28 days prior to the first dose, including chemotherapy, targeted therapy, anti-angiogenic drugs, biological therapy, immunotherapy, radiotherapy, etc., or received traditional Chinese medicine or herbal medicines with clear anti-tumor effects within 1 week prior to the first dose.
* Treatment with medications that may affect the metabolism of the investigational drug within 14 days prior to the first dose, such as strong CYP3A inhibitors, strong CYP3A inducers, or P-gp inhibitors.
* Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of the investigational drug.
* Known to have active infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis.
* Known history of infection with human immunodeficiency virus (HIV).
* Active gastrointestinal disease or other condition that will interfere significantly with the swallowing, absorption, distribution, metabolism, or excretion of oral therapy.
* For female subjects: currently pregnant or lactating.
* Presence of clinically significant severe ophthalmic examination abnormalities at screening, such as retinitis pigmentosa, maculopathy, active ocular infection, etc., or known history of retinal or optic nerve disorders, such as retinitis pigmentosa, maculopathy, glaucoma, optic neuritis, etc.
* Participants with a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or a history of melena or hematemesis within 2 months before dosing, or those who may experience visceral hemorrhage as determined by the investigator.
* Clinically symptomatic moderate to severe ascites or pleural effusion, or presence of uncontrolled or moderate to severe pericardial effusion.

Where it's running

• Peking University Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Hebei Cancer Hospital of Chinese Academy of Medical Sciences
  Langfang, Heibei, China Recruiting
• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yongchao Li
• Email: liyongchao@groovymedicine.com
• Phone: 86-13336882732

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SIBP-A10 injection for adults with advanced malignant tumors

  This trial will test whether SIBP-A10 injections are safe and tolerable and to identify the best dose for adults with advanced metastatic tumors.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Dalian, Liaoning · NCT07205198

• AL58805 treatment for people with advanced solid tumors.

  This Phase I dose-escalation trial will test different oral doses of AL58805 in people with advanced solid tumors who have exhausted standard treatment options.

  Recruiting Phase 1 Advenchen Laboratories, LLC · Changsha, Hunan · NCT07179081

• Testing MDX2004 at increasing doses in adults with advanced tumors

  This will test whether different doses of the experimental drug MDX2004 are safe and can shrink tumors in adults with advanced or metastatic cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Liverpool, New South Wales and 5 other locations · NCT07110584

• Personalized neoantigen vaccine combined with radiotherapy for advanced tumors

  This study is testing a personalized vaccine made from a patient's own tumor cells combined with radiotherapy to see if it can help people with advanced tumors that haven't responded to standard treatments.

  Recruiting Phase 2 The University of Hong Kong-Shenzhen Hospital · Shenzhen, Guangdong and 1 other locations · NCT06314087

• Evaluating CS23546 for patients with advanced tumors

  This study is testing a new treatment called CS23546 to see if it's safe and how well it works for people with advanced tumors.

  Recruiting Phase 1 Chipscreen Biosciences, Ltd. · Guangzhou · NCT06245122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.